Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

This phase II trial tests how well atezolizumab works in treating patients with human papillomavirus (HPV) related oropharyngeal squamous cell carcinoma that is able to be removed with surgery (resectable). Immunotherapy with atezolizumab, may include changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

Trial Details

NCT ID
NCT06254911
Phase
PHASE2
Sponsor
Emory University
Status
RECRUITING
Cancer Type
Squamous Cell Head and Neck Cancer
Interventions
  • Atezolizumab
  • Transoral Surgery with cervical lymphadenctomy (neck dissection)
  • Computed Tomography
  • Magnetic Resonance Imaging
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • The subject is \>= 18 years old on the day of consent
  • Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during t…
  • Female subjects of childbearing potential must not be pregnant at screening. Females of childbearing potential are defined as premenopausal females…
  • A male participant must agree to use a contraception as detailed in this protocol during the treatment period and for at least during the active tr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Head and Neck Cancer Trials on Trialify →